Physicians' preferences for active-controlled versus placebo-controlled trials of new antihypertensive drugs

Journal of General Internal Medicine

Volumn 17, Issue 9, 2002, Pages 689-695

  Halpern, Scott D ^a,b   Berlin, Jesse A ^a,b   Asch, David A ^a  

^a Center for Bioethics   (United States)

^b Center for Education and Research on Therapeutics   (United States)

Author keywords

Antihypertensive drugs; Clinical trials; Ethics; Physicians' preferences; Placebo controlled trials

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ARTICLE; CONTROLLED STUDY; DRUG RESEARCH; DRUG SCREENING; ERROR; EVALUATION; FEMALE; HUMAN; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MALE; MEDICAL ETHICS; PATIENT REFERRAL; PHYSICIAN; PRESCRIPTION; PRIMARY MEDICAL CARE; PUBLIC HEALTH; QUESTIONNAIRE; RISK; STANDARD;

BIOMEDICAL AND BEHAVIORAL RESEARCH; EMPIRICAL APPROACH;

ANTIHYPERTENSIVE AGENTS; ATTITUDE OF HEALTH PERSONNEL; CLINICAL TRIALS; DATA COLLECTION; DRUG EVALUATION; FEMALE; HUMANS; HYPERTENSION; MALE; PHYSICIAN'S PRACTICE PATTERNS; PLACEBOS; PRESCRIPTIONS, DRUG; QUESTIONNAIRES; REFERRAL AND CONSULTATION; RISK;

EID: 0036042898     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1497.2002.11024.x     Document Type: Article

References (38)

1. The ethics of using placebo in hypertension clinical trials
2. Is the use of placebo in antihypertensive drug studies ethical?
3. Placebo-associated blood pressure response and adverse effects in the treatment of hypertension
4. Placebo-controlled trials are unethical in clinical hypertension research
5. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases
6. When are clinical trials of a given agent vs. placebo no longer appropriate or feasible?
7. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues
8. Ethical considerations in the planning of hypertension treatment trials
9. An additional basic science for clinical medicine: II. The limitations of randomized trials
10. Scientific challenges in the application of randomized trials
11. Randomised clinical trials with clinician-preferred treatment
12. Validity versus generalizability in clinical trial design and conduct
13. Who will enroll? Predicting participation in a phase II AIDS vaccine trial
14. Trials to assess equivalence: The importance of rigorous methods
15. Design and interpretation of equivalence trials
16. Scientific value and validity as ethical requirements for research: A proposed explication
17. What makes clinical research ethical?
18. Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study
19. Ethical considerations in the planning of hypertension treatment trials
20. A randomized trial of $5 versus $10 monetary incentives, envelope size, and candy to increase physician response rates to mailed questionnaires
21. Physicians' reasons for not entering eligible patients in a randomized clinical trial of adjuvant surgery for breast cancer
22. Oncologists' reluctance to accrue patients onto clinical trials: An Illinois Cancer Center study
23. Integrating conflicting professional roles: Physician participation in randomized clinical trials
24. Physician participation in a randomized clinical trial for ocular melanoma
25. Fundamental dilemmas of the randomized clinical trial process: Results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators
26. Breast cancer prevention study aims to overcome drug bias
27. Tribulations for clinical trials. Poor recruitment is hampering research
28. Comparison of vignettes, standardized patients, and chart abstraction: A prospective validation study of 3 methods for measuring quality
29. Placebo-controlled trials in type 2 diabetes
30. Statistical analysis to settle ethical issues
31. The placebo problem remains
32. Impact of randomized clinical trials on medical practice
33. Physicians' use of outcomes data: Moral conflicts and potential resolutions
34. Inadequate management of blood pressure in a hypertensive population
35. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a goal in hypertension treatment (INSIGHT)
36. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study